AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Core Insights - AbCellera and Biogen Inc. have formed a strategic collaboration aimed at discovering antibodies for a novel target that facilitates the delivery of biotherapeutics to the brain, addressing a significant challenge in neuroscience [1] - The collaboration is expected to unlock new treatment approaches for neurological conditions, as stated by AbCellera's SVP, highlighting the importance of overcoming the blood-brain barrier [1] Company Overview - AbCellera is focused on revolutionizing antibody drug discovery, integrating expert teams, technology, and data science to expedite the development of antibody-based medicines across various therapeutic areas [2] - The company aims to provide a competitive advantage to biotechs and pharmaceutical companies, enabling them to reduce costs and address complex drug development challenges [2]